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 2 
Abstract  30 
Endometriosis is a complex, heterogeneous, chronic inflammatory condition impacting 
approximately 176 million women worldwide. It is associated with chronic pelvic pain, 
infertility and fatigue, and has a substantial impact on health-related quality of life. 
Endometriosis is defined by the growth of endometrial-like tissue outside the uterus, typically 
on the lining of the pelvic cavity and ovaries (known as ‘lesions’). Macrophages are complex 35 
cells at the centre of this enigmatic condition; they are critical for the growth, development, 
vascularisation and innervation of lesions as well as generation of pain symptoms. In health, 
tissue-resident macrophages are seeded during early embryonic life are vital for development 
and homeostasis of tissues. In the adult, under inflammatory challenge, monocytes are recruited 
from the blood and differentiate into macrophages in tissues where they fulfil functions, such 40 
as fighting infection and repairing wounds. The interplay between tissue-resident and recruited 
macrophages is now at the forefront of macrophage research due to their differential roles in 
inflammatory disorders. In some cancers, tumour-associated macrophages are comprised of 
tissue-resident macrophages and recruited inflammatory monocytes that differentiate into 
macrophages within the tumour. These macrophages of different origins play differential roles 45 
in disease progression. Herein, we review the complexities of macrophage dynamics in health 
and disease and explore the paradigm that under disease-modified conditions, macrophages 
that normally maintain homeostasis become modified such that they promote disease. We also 
interrogate the evidence to support the existence of multiple phenotypic populations and origins 
of macrophages in endometriosis and how this could be exploited for therapy.  50 
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1. Background 
Endometriosis is defined by the presence of endometrial-like tissue outside the uterus 75 
(‘lesions’), typically on the lining of the pelvic cavity (peritoneum) or on the ovaries. 
Endometriosis is a heterogeneous disease, and lesions can be categorized into three sub-types: 
superficial peritoneal, deep (infiltrating) and ovarian (“endometriomas”), where more than one 
sub-type can exist in the same patient and superficial peritoneal endometriosis is the most 
common form of disease(1, 2). It is associated with debilitating chronic pelvic pain, infertility 80 
and fatigue. It is estimated to affect 6-10% of women of reproductive age(3), up to 50% of 
infertile women(4) and is prevalent in 71-97% of women with chronic pelvic pain(5). 
Endometriosis-associated symptoms can negatively impact mental, physical and social 
wellbeing and quality of life(6). Poor pregnancy outcomes are also associated with the disease, 
including preterm labour, pre-eclampsia, ectopic pregnancy, miscarriage and intrauterine 85 
growth restriction(7). Endometriosis has a significant socioeconomic impact, costing the UK 
an estimated £8.5 billion pounds each year, with societal cost being mostly attributed to loss of 
productivity(8, 9). Diagnosis from onset of symptoms can take an average of 7-8 years. 
Generally, a diagnosis of endometriosis is achieved by laparoscopic evaluation of the pelvis, 
however imaging techniques such as transvaginal sonography and magnetic resonance imaging 90 
may be utilised to diagnose deep lesions and endometriomas(10-12). 
 
Endometriosis lesions are characterised by the presence of ectopic endometrial-like tissue 
containing glands and stroma, however recent re-evaluation of disease definition suggests that 
fibrosis and smooth muscle cells are more consistent features of lesions(13). Endometriosis is 95 
classified as an estrogen-dependent chronic inflammatory condition: symptoms are modulated 
by ovarian hormones and lesions generate intense inflammation within the pelvic cavity.  
Lesions also become vascularized and are infiltrated by sensory nerve fibres (Fig.1). The 
ectopic endometrial cells and local inflammatory environment activate nerve fibres in lesions, 
establishing a dialogue with the central nervous system and generating pain in the condition. 100 
Lesions behave like the eutopic endometrium and exhibit cyclical bleeding into the pelvic 
cavity in response to ovarian hormones, and this acts to potentiate inflammation(14).  Disease 
classification (rAFS / rASRM) is currently based on lesion size, location, extent of lesion 
infiltration into tissue and the presence of adhesions. Classification ranges from stage I 
(‘minimal’) to stage IV (‘severe’)(15).  105 
Current treatments for endometriosis aim to alleviate endometriosis-associated pain and/or to 
treat infertility associated with the disease and include surgical and medical management(2, 3). 
Ovarian suppression limits activity and growth of lesions, leading to reduced pain symptoms. 
Common methods of ovarian suppression include oral contraceptives and gonadotrophin-
releasing hormone (GnRH) agonists(16) with add-back HRT. Whilst ovarian suppression may 110 
alleviate pain symptoms, treatment is also contraceptive and therefore inappropriate for women 
aiming to conceive. Additionally, GnRH agonists are associated with side effects such as 
memory loss, insomnia and hot flushes in a recent study of endometriosis patients with long 
term use(17). Treatments can also include non-steroidal anti-inflammatory drugs such as 
ibuprofen, however long-term pain management for women with endometriosis often 115 
encompasses a combination of treatments. As well as medical therapy, laparoscopic surgery to 
remove lesions can provide symptom relief in some patients, however up to 50% of women 
experience a relapse of symptoms within two years after surgery(11). Current treatment options 
lack significant clinically proven benefit and aim at alleviating symptoms, rather than treating 
disease(18). Consequently, there is a compelling clinical need for new non-hormonal 120 
treatments that have fewer side effects and effectively treat endometriosis over a life course, 
without the need for repeated surgeries or suppression of fertility. 
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Figure 1. Endometriosis is a chronic inflammatory condition. Endometriosis is characterised 
by the presence of endometrial-like tissue found outside the uterus, most commonly in the 
peritoneal cavity. Endometriosis lesions are heterogenous but usually contain endometrial 125 
stromal cells and epithelial glands, immune cell infiltrates and are vascularised and innervated 
by nerves. Created using Biorender.com. 
 
2. Aetiology and natural history 
 130 
It is widely accepted that endometriosis is a multifactorial disease and the pathophysiology of 
endometriosis can certainly be associated with a number of elements that clearly contribute to 
disease. Evidence suggests that endometriosis has a heritable component due to high familial 
incidence of the disease(19-22). A meta-analysis of eight genome-wide association studies  
(GWAS) elucidated six loci associated with endometriosis(23)  Genes implicated in disease 135 
included those involved in the regulation of epithelial cells and hormone metabolism, 
specifically genes involved in regulating hormone responses in tissues (24, 25). These GWAS 
results are not surprising since the symptoms of endometriosis are modulated by ovarian sex 
steroids; early age at menarche is a risk factor for development of endometriosis, suggesting 
increased exposure to estrogen may incur increased risk of disease(26). Endometriosis lesions 140 
aberrantly express a number of steroidogenic enzymes including aromatase and 17β-
hydroxysteriod dehydrogenase (17β-HSD), this results in increased synthesis and decreased 
metabolism estrogen (27-29)such that local levels remain high. Estrogen signalling modulates 
a large number of down-stream disease processes within endometriosis lesions, which are 
reviewed in(30, 31) and (32). Immune cell dysfunction is also intrinsically linked to the 145 
pathophysiology of endometriosis. Alterations in immune cell populations have been observed 
in the peritoneal fluid of women with endometriosis; specifically, women with endometriosis 
have more peritoneal macrophages (33), neutrophils and dendritic cells (34). Function is also 
perturbed: NK cells have reduced cytotoxicty (35, 36), and disease severity is positively 
correlated with NK cell killing capacity (37). Peritoneal macrophages also exhibit impaired 150 
phagocytosis (38). Macrophages are the most abundant immune cells present within 
endometriosis lesions and are evidently central to the pathophysiology of endometriosis. Whilst 
studies have highlighted clear functional roles for macrophages in the disorder, little is known 
regarding the origins and phenotypic heterogeneity of macrophages in endometriosis.   
 5 
Our understanding of endometriosis aetiology remains limited. It is being increasingly 155 
recognised that different sub-types of endometriosis may arise from different origins, however 
evidence for this is still limited (39, 40). A number of theories are discussed below and we 
speculate on how the origin and role of macrophages may differ in each scenario: 
The most widely accepted theory was postulated in 1927 by John Sampson, who observed that 
during menstruation, endometrial tissue can reflux back up the fallopian tubes and into the 160 
pelvic cavity, a physiological process known as ‘retrograde menstruation’. Although this 
process occurs in ~90% of women, only in some does refluxed endometrial tissue form 
endometriosis lesions (41) and the mechanisms underpinning the attachment of endometrial 
tissue and lesion development remain elusive. It could be predicted, and mouse studies have 
demonstrated that macrophages originating from the endometrium contribute to peritoneal 165 
endometriosis lesions(42). These endometrial macrophages could be pivotal in the 
establishment of lesions since it has previously been demonstrated that macrophages trafficking 
to the endometrium are most abundant during repair following endometrial breakdown and 
shedding with a presumed role in repairing the denuded functional layer of the endometrium 
(43). However, evidence supporting this hypothesis is still absent.   Another theory based on 170 
the dissemination of cells from the uterus into the peritoneal cavity suggests that neonatal 
retrograde reflux of endometrial stem/progenitor cells could be responsible for development of 
lesions. Visible vaginal bleeding is observed in 3-5% of female neonates, whereas occult 
bleeding may occur at a frequency of between 25-60% (44). Bleeding in the immediate 
postnatal period is similar to menstrual bleeding as it occurs in response to hormone withdrawal 175 
from in utero progesterone exposure. This theory suggests that stem/progenitor cells could 
implant into the peritoneal wall where they may remain dormant until adolescence, when 
elevated estrogen levels may then promote the proliferation and growth of seeded endometrial 
cells. Whilst this theory represents a plausible mechanism of lesion formation, current evidence 
is lacking and proof that endometrial stem/progenitor cells are present in the peritoneal tissue 180 
of pre-pubescent girls is absent.  The coelomic metaplasia theory suggests that endometriosis 
lesions arise as the result of metaplastic differentiation of the coelomic epithelium into 
endometrial cells and is supported by evidence suggesting endometriosis lesions can be found 
in women without a uterus (45). The formation of endometriosis lesions at sites distant from 
the peritoneal cavity (46, 47), as well as identification in men on rare occasions (48) supports 185 
the theory. Upon development of lesions at the onset on adolescence (neonatal stem cell theory) 
or following metaplasia it would be expected that monocytes are recruited to the site of the 
lesion and/ or that peritoneal macrophages may traffic into the developing lesion and activate 
repair processes that facilitate establishment of new endometrial-like explants. Notably, stem 
cells and macrophages are known to have a reciprocal relationship whereby stem cells can 190 
contribute to macrophage activation and phenotype during regenerative processes and 
macrophages can dictate accumulation of progenitor / stem cell-like cells (49). In 
endometriosis, mesenchymal stem-like cells promote macrophages to adopt a pro-repair 
phenotype (50) but further studies regarding the relationship between stem cells and 
macrophages in endometriosis are currently limited. Müllerianosis (müllerian rests; normal 195 
endometrial, endosalpingeal, and endocervical tissue) predicts that developmentally displaced 
tissue are incorporated into normal organs during organogenesis (51). Occurrence of deep 
infiltrating endometriosis particularly lends itself to this theory, where endometrial tissue is 
found deep within the organ structure. Speculation may infer a role for tissue-resident 
macrophages in lesions resulting from developmentally displaced endometrial-like tissue. 200 
Upon activation of a ‘dormant’ lesion laid down during organogenesis the tissue-resident 
macrophages may change phenotype and proliferate such that they promote inflammation, 
growth and invasion of the lesion. Inflammation arising upon activation of a dormant lesion 
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may also lead to the recruitment of monocytes that differentiate into macrophages such that 
endometriosis lesion-resident macrophages are constituted by tissue-resident and monocyte-205 
derived macrophages similar to what occurs in tumours(52). Any differences existing in 
macrophage origin, phenotype and function across the different subtypes of endometriosis 
lesions remain unknown.  
3. The macrophage: a complex cell at the centre of an enigmatic condition 
Inflammation and immune cell dysfunction are central to the pathophysiology of 210 
endometriosis.  Whilst a number of leukocytes exhibit altered numbers and function in 
endometriosis, it is evident that macrophages play an unrivalled role in disease pathogenesis. 
We and others have demonstrated that macrophages are critical for licensing lesion growth, 
promoting vascularization and innervation as well as contributing to pain in the disorder(53-
55). Lessons from diverse tissues also place macrophages at the centre of disease states such 215 
as liver injury(56), multiple sclerosis(57) and cancer(52). Tissue context ultimately dictates the 
role that macrophages play in disease but a recurring theme indicates that the ontogeny of the 
macrophages in diseased tissues determines how they respond and contribute to pathogenesis. 
Below, we review the available literature on macrophage ontogeny, phenotype and function in 
health and then focus on their role during inflammation and disease states. Ultimately, we 220 
discuss the role that macrophages play in endometriosis in light of what can be learnt from 
other disease states.   
3.1 Macrophages have different origins and diverse phenotypes 
3.1.1 Macrophage ontogeny. Macrophages are mononuclear phagocytes that play critical roles 
in immunity (phagocytosing pathogens, apoptotic cells and debris, antigen presentation and 225 
modulation of other leukocyte populations). They are present in all tissues of the body(58) (59) 
and play diverse tissue specific roles in maintaining homeostasis. Much of our knowledge 
regarding macrophage ontogeny is derived from studies conducted in mice. Macrophages are 
derived from three key populations; the yolk sac of the embryo, the foetal liver and postnatally, 
haematopoiesis in the bone marrow. The earliest macrophages arise from erythro-myeloid 230 
progenitors (EMPs) produced during primitive haematopoiesis in the extra-embryonic yolk sac 
at embryonic day (E)7.5 and 8.25. After blood circulation is established, EMP derived 
macrophages seed foetal tissue. Excluding microglia, these macrophages are partially or fully 
replaced by monocytes originating from the foetal liver, which differentiate into macrophages 
in tissues. Foetal liver monocyte-derived macrophages can persist into adulthood and form the 235 
tissue resident macrophage population, undergoing self-renewal, for example in the 
peritoneum, spleen, lung, skin and liver. In other organs, tissue macrophages derived from 
foetal liver monocytes are gradually replaced by recruited monocytes from the bone marrow. 
This process occurs in tissues such as the gut and dermis (60-64). 
In humans, peripheral blood monocytes form two main populations; CD14hi CD16lo and  240 
CD14lo CD16hi, although an intermediate population can be identified. The CD14hi CD16lo  
(classical) subset is the most abundant in the blood. Under inflammatory conditions, classical 
monocytes extravasate into tissues, differentiate into macrophages or dendritic cells (65) and 
fulfil  functions such as clearance of apoptotic bodies, stimulating angiogenesis and restoring 
integrity of tissues (66). CD14lo CD16hi (‘non-classical’) monocytes also exhibit extravasation 245 
into tissues during inflammation, but they infiltrate tissues later in the inflammatory process 
and exhibit a bias towards differentiating into ‘wound-healing’ macrophages(67). A key role 
of the non-classical monocyte population is to patrol the blood vessels along the endothelial 
cell layer, providing immunosurveillance of vasculature and the surrounding tissues(68). 
 7 
Classical monocytes also patrol tissues and play a homeostatic role in steady state conditions, 250 
without differentiating into macrophages(69). Classical and non-classical monocytes in 
humans are analogous to Ly6Chi classical and Ly6Clo non-classical monocytes in mice and 
exhibit significant homology at transcriptional analysis (70, 71). In mice, classical monocytes 
can be classified as Ly6Chi CX3CR1lo CD43loCCR2hi, and non-classical monocytes as Ly6Clo 
CX3CR1hi CD43hiCCR2lo, with all monocyte populations being CD11bhi F4/80int(65).  255 
 
3.1.2 Macrophage phenotype. Macrophages respond to their local microenvironment and 
change both their transcriptome and phenotype in response to local signals (72). Historically, 
macrophages have been divided into either ‘M1’ classically or ‘M2’ alternatively activated 
cells. Classically activated macrophages are associated with inflammation, and express pro-260 
inflammatory markers. Alternatively activated macrophages are associated with homeostasis, 
wound healing and immunomodulation(73). These extreme polarisation states only really exist 
in vitro, where studies commonly use stimulation with granulocyte-macrophage colony-
stimulating factor (GM-CSF) and the cytokine IFN-γ (Interferon γ) to generate M1 
macrophages, and stimulation with macrophage colony-stimulating factor (M-CSF) and the 265 
cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) to generate M2 activated 
macrophages(74).  Whilst this classification system is a useful tool for investigating 
macrophages at extremes of activation, it is now appreciated that in vivo macrophages exhibit 
a broad spectrum of phenotypes that are tissue and disease specific, and the M1/ M2 system 
cannot represent the diverse nature and complexities of macrophage phenotype (75, 76). 270 
Transcriptional analysis of mouse macrophage populations from different tissues demonstrates 
minimal overlap in mRNA expression, reflecting a divergence in gene expression patterns(77). 
This heterogeneity reflects the ability of macrophages to modulate their gene expression in 
response to local tissue signals, becoming specialised to their tissue niche, be that in a healthy 
or diseased state. In disease, macrophages may modulate their phenotype dependent on disease 275 
stage or severity, and the mechanisms behind this are crucial for understanding their exact role 
in pathogenesis. Thus, defining macrophage phenotypes in disease states, with the potential of 
modulating macrophage phenotype or specifically targeting disease specific macrophages for 
clinical benefit is a key focus for research(72, 78-80).  
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Figure 2. Macrophages are mononuclear phagocytes. Tissue macrophages are seeded during 280 
foetal life from the foetal liver and yolk sack and undergo self-renewal. In adults, monocyte 
precursors extravasate from the bone marrow into the circulation, where they can then 
infiltrate into tissues and differentiate into macrophages. In tissues, macrophages modulate 
their phenotype dependent on local cytokines and growth factors to specific tissue or disease-
associated phenotypes.  285 
 
3.2. Endometrial macrophages  
The endometrium is a unique and highly dynamic tissue that undergoes cyclic proliferation, 
differentiation, shedding (menstruation) and repair in response to ovarian-derived estrogen and 
progesterone during the menstrual cycle. In the normal cycling endometrium, an influx of 290 
macrophages occurs during the secretory and menstrual phases, along with a concomitant 
increase in macrophage-derived cytokines and proteases (81). Evidence from a mouse model 
of endometrial breakdown and repair identified an influx of classical monocytes which 
differentiated into macrophages in the endometrium during the repair phase of the menstrual 
cycle (43). Monocyte extravasation from blood vessels into the endometrium is regulated by 295 
CCL2 (82, 83) and CX3C chemokine receptor 1 (CX3CR1) (84). The influx of macrophages 
into the endometrium is in line with the numerous roles they are presumed to play in modulating 
endometrial differentiation, breakdown and repair. During the proliferative phase, 
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macrophages have been postulated to play a role in regeneration and proliferation of the 
functional layer of the endometrium and express activation and adhesion markers CD54, CD69 300 
and CD71(85). Macrophages are also implicated in regulating gland remodelling(86) and 
angiogenesis during the secretory phase via production of vascular endothelial growth factor 
(VEGF)(87). At menstruation macrophages play a role in initiation of endometrial shedding by 
secreting matrix metalloproteinases (MMPs)(88). Specifically, secretion of MMP-12, MMP-9 
and MMP-14 are required for the breakdown of the functional layer of the endometrium during 305 
menstruation (89-91).  
 
In response to estrogen, macrophages increase their proliferative capacity and undergo 
activation to adopt a phenotype which represents a more 'wound healing-like' population (92). 
Thus, estrogen signalling can accelerate the wound healing process and this is in part regulated 310 
by increasing the production of macrophage-derived proteases, MMPs, fibroblast growth 
factor, VEGF and cytokines such as resistin like alpha (RELMα)(92-94). Endometrial 
macrophages do not express the progesterone receptor (95), however macrophage gene 
expression is significantly altered in response to progesterone (96) suggesting an indirect 
method of regulation. Interestingly, exposure to cortisol was demonstrated to increase 315 
expression of angiogenic genes such as CXCL2, CXCL8, and VEGFC in macrophages in vitro, 
suggesting that local cortisol levels could be important for regulating angiogenesis within the 
remodelling endometrium(97). Taken together this evidence indicates that macrophages are 
key players in augmenting dynamic remodelling and repair in the endometrium and this is 
regulated by exposure to local cytokines, growth factors and hormones that modulate their 320 
phenotype, function and recruitment throughout the menstrual cycle. However, compared to 
other tissue macrophages, the phenotype and function of endometrial macrophages and the 
mechanisms governing their recruitment and activation are significantly less well 
characterized. 
 325 
3.3. Peritoneal macrophages 
 
3.3.1 Mouse. Peritoneal cavity macrophages are one of the most studied macrophage 
populations in mice, largely due to their ease of isolation. Two subsets of peritoneal 
macrophages are recognised in mice based on differential expression of F4/80 and MHC II. 330 
The tissue resident, so called 'large' (due to their larger size) peritoneal macrophages (LpM) 
are F4/80hi, MHC IIlo and the monocyte-derived 'small' peritoneal macrophages (SpM) are 
F4/80lo MHC IIhi (98). LpM are the most abundant macrophage population in the peritoneal 
cavity at steady state and form the tissue resident population, they are phagocytic and perform 
immunosurveillance and homeostatic roles in the peritoneal cavity (98) as well as mediating 335 
recruitment and maintenance of B1 B cells.  They are also linked to regulation of intestinal 
immunity(99). LpM self-renew and the proliferative capacity of LpM is regulated by GATA-
binding factor 6 (Gata6), a transcription factor uniquely expressed by LpM in the peritoneal 
cavity, which also regulates macrophage phenotype (100). In mice, the LpM population 
consists primarily of embryonic-derived cells, however monocyte-derived macrophages do 340 
replace embryonic-derived LpM over time, a process that is highly sex and age dependent, and 
slower in females. Over time, Ly6Chi monocytes enter the peritoneal cavity in a CCR2-
dependent manner and differentiate transiently into SpM, prior to transitioning into tissue 
resident LpM (101). Thus, the LpM constitute both embryonic and monocyte-derived cells and 
the two populations have been shown to be transcriptionally distinct from each other (101). 345 
SpM are implicated in the inflammatory response in the peritoneal cavity, however their role 
in the steady state peritoneal cavity remains unclear(102). 
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3.3.2 Human. In humans, macrophages constitute 50% of peritoneal cavity leukocytes (103). 
Tissue resident peritoneal macrophages have been defined by high expression of complement 350 
receptor of the immunoglobulin superfamily (CRIg) and low expression of CCR2. These cells 
are highly phagocytic and more numerous in steady state, also displaying similar transcriptional 
profiles to the mouse LpM population(104). Human monocyte-derived macrophages in the 
peritoneal cavity, anologous to F4/80lo MHC IIhi SpM in the mouse, have been defined as 
CRIglo, CCR2hi. This CRIglo, CCR2hi population in humans has a reduced phagocytic capacity 355 
and is lower in number compared to CRIghi CCR2lo tissue macrophages, consistent with 
characteristics of SpM. It must be noted however that in humans, Gata6 was found to be more 
highly up-regulated in the pro-inflammatory CRIglo CCR2hi population(104), highlighting that 
key differences between human and mouse peritoneal macrophages exist, and further research 
is critically required to clarify these differences.  360 
 
3.3.3 Peritoneal macrophage dynamics during inflammation. Under inflammatory conditions, 
LpM respond to stimuli in a phenomenon known as the macrophage disappearance reaction 
(MDR) (105): in mice the LpM compartment undergoes a dramatic reduction in numbers 
largely by migration to the omentum, mediated by retinoic acid and Gata6 (106). The degree 365 
of loss in the LpM population is highly dependent on the dose of inflammatory stimuli and has 
been studied in a number of inflammatory models, such as lipopolysaccharide (LPS), zymosan 
or thioglycollate induced peritonitis (107-109). LpM that persist during inflammation have 
been hypothesised to play a regulatory role in the peritoneal cavity by secretion of IL-10, an 
anti-inflammatory cytokine which has also been shown to regulate inflammatory SpM number 370 
(109). LpM also play a key role in clearance of apoptotic cells during inflammation (108), and 
exhibit high expression of T-cell immunoglobulin and mucin domain containing 4 (Tim4) 
which recognises phosphatidyl-serine on apoptotic cell bodies (110). Upon resolution of 
inflammation, the depleted LpM population increases its proliferative capacity through a 
colony stimulating factor 1 receptor (Csf-1r) mediated mechanism to restore LpM number 375 
(107). Interestingly, LpM have been shown to infiltrate the liver by a non-vascular route in 
response to the damage-associated molecular pattern molecule (DAMP) ATP, where they play 
a key role in regeneration and tissue repair in the liver after sterile injury, modulating their 
phenotype in response to local tissue microenvironmental cues (111). This migration implies 
that LpM have the ability to execute wound repair and tissue regeneration in visceral organs. 380 
Furthermore, with a reduction of LpM numbers a concurrent increase in SpM and inflammatory 
Ly6Chi monocytes is observed in a number of mouse models of peritoneal inflammation (105). 
SpM exhibit a pro-inflammatory response when challenged with LPS in vitro, producing high 
levels of chemokine (C-C motif) ligand 5 (Ccl5), chemokine (C-C motif) ligand 3 (Ccl3) and 
tumor necrosis factor-α (Tnf-α), as opposed to LpM which produce G-CSF and GM-CSF under 385 
LPS stimuli (102).  In an in vivo model of peritonitis, SpM also produce high amounts of pro-
inflammatory cytokines including Tnf-α, interleukin-1β (Il-1β) and Ifn-γ (112), and are critical 
for clearance of infection in the peritoneal cavity after bacterial challenge in the mouse (113). 
The ability of SpM to respond to inflammatory stimuli by producing pro-inflammatory 
cytokines enables rapid response to immunological challenge in the peritoneal cavity. At 390 
resolution of inflammation, SpM have been shown to undergo apoptosis (108) but can also  
migrate to local draining lymph nodes (114). However, SpM have also been shown to persist 
in the cavity and can eventually differentiate into F4/80hi MHC IIlo cells (115), suggesting that 
inflammation has the potential to alter the complement of peritoneal cavity macrophage 
populations, even after homeostasis has been restored. The multiple fates of SpM reflect the 395 
heterogeneity in this cell compartment, but the roles of SpM sub-populations in inflammation 
are still largely undefined. In summary, under steady-state / homeostatic conditions LpM 
exhibit an immune-surveillance and immune-regulatory role and act to remove apoptotic and 
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senescent cells. The roles of SpM are less well defined but the markers they express suggests 
roles in antigen presentation and T cell activation. Inflammatory challenge with thioglycolate, 400 
zymosan or LPS (lipopolysaccharide) causes loss of LpM and expansion of SpM via monocyte 
recruitment and differentiation. New SpM are pro-inflammatory, expressing high levels of 
Tnfa, Il-1b and Ifng and are better able to engulf microbes compared to homeostatic SpM. Of 
note, type-2 inflammation characterized by elevated levels of IL-4 does not induce MDR and 
instead F4/80hi LpM accumulate in the peritoneal cavity and exhibit a pro-repair 405 
phenotype(116).  Thus, it seems that under different inflammatory challenge LpM are biased 
to exhibit a pro-repair phenotype whilst SpM adopt a pro-inflammatory phenotype. 
Mechanistic studies on peritoneal macrophages in humans are challenging and therefore 
knowledge of this physiological process in humans is minimal. 
3.4. Macrophages can promote disease 410 
The unique and diverse roles that macrophages play in the maintenance of healthy tissues is 
mirrored by their pivotal roles in development, maintenance and progression of a number of 
diseases(72). Peritoneal cavity macrophage perturbations and functional dysregulation are 
linked to a number of adverse clinical outcomes. For example, an increase in peritoneal 
macrophages was associated with negative outcomes in patients with peritonitis (109), and 415 
dysregulation of peritoneal macrophages has been linked to acute pancreatitis, where peritoneal 
macrophages produce increased levels of pro-inflammatory cytokines that exacerbate disease 
(115). Conversely, macrophages have been shown to be protective against the formation of 
adhesions, a common complication after abdominal surgery (117) and indicating that 
macrophage dysfunction could contribute to adhesion formation. Thus, macrophages are 420 
intrinsically linked to disease in the peritoneal cavity in humans   
Although endometriosis is a benign condition a number of parallels can be drawn between the 
condition and cancer (118). Macrophages are unambiguously at the centre of the 
pathophysiology of both diseases. Macrophage infiltration in tumours is a predictor of poor 
clinical outcomes in malignancy (119, 120), attributed to the fact that macrophages promote 425 
initiation, progression and metastasis in most cancers (75). In the last decade a major focus has 
been to define the populations that constitute tumour-associated macrophages (TAMs). In a 
mouse model of breast cancer, Ly6Chi inflammatory monocytes are recruited to metastatic sites 
via a CCR2/CCL2 mediated mechanism to form TAMs. Inhibition of CCL2/CCR2 signalling 
with an anti-CCL2 antibody inhibited monocyte recruitment thereby inhibiting metastasis and 430 
prolonging survival of the mice(121). Similarly, mouse models of Lewis lung carcinoma 
demonstrated that TAMs were derived from CCR2 driven recruitment of Ly6Chi monocytes 
and blockage of CCL2 decreased tumour growth (122, 123). Furthermore, tissue resident 
macrophages have also been implicated in cancer pathophysiology and can contribute to the 
TAM population. For example, in a mouse model of pancreatic ductal adenocarcinoma, Zhu et 435 
al demonstrated using a parabiosis model that TAMs were derived from both embryonically 
derived tissue resident macrophages as well as from circulating Ly6Chi monocytes. During 
tumour development embryonically derived macrophages expanded via in situ proliferation 
and had a pro-fibrotic role in tumours. Using a Csf-1r neutralizing antibody and clodronate 
liposome treatment to deplete tissue resident macrophages a reduction in tumour size and 440 
increased survival of mice was observed. Monocyte-derived macrophages however played a 
key role in antigen presentation. Use of CCR2 knockout mice or a CCR2 inhibitor to prevent 
recruitment of Ly6Chi monocytes did not affect tumour growth (52). This study highlights the 
importance of defining the ontogeny of TAMs in order to decipher which populations are 
fundamentally required for tumour growth, with the aim of improving clinical outcomes.  445 
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Whilst TAMs may have multiple origins, it has been demonstrated that the tumour 
microenvironment can modulate macrophage phenotype to promote malignancy, indicating 
that origin does not wholly define function when macrophages are exposed to cytokines and 
growth factors locally in the tumour. A number of different macrophage populations within 
tumours have been described which play differential roles and have different phenotypes. For 450 
example, populations of invasive, perivascular, metastasis associated, angiogenic (Tie2+) and 
immunosuppressive macrophages which secrete high levels of IL-10 have been described (75).  
Detailed profiling of hepatocellular carcinoma biopsies demonstrated the presence of various 
macrophage sub-types in tumours that had both pro and anti-tumoral properties(124).  
3.5. The role of macrophages in endometriosis 455 
 
3.5.1. Macrophage ontogeny in endometriosis. Whilst a role for macrophages in endometriosis 
pathophysiology is established (and discussed below), the ontogeny of endometriosis-
associated macrophages is still poorly understood. Greaves et al demonstrated in a syngeneic 
mouse model of endometriosis that lesion resident macrophages are derived from both the 460 
(donor) endometrium and (recipient) infiltrating macrophage populations (42)(Fig.3). These 
infiltrating macrophage populations are likely to constitute peritoneal or recruited monocyte-
derived macrophages, however the exact origins of these populations is currently unknown. 
Although peritoneal macrophages contribute to inflammation in endometriosis, it remains 
unknown whether they infiltrate endometriosis lesions and thus the role these cells play within 465 
the ectopic tissue is not known. Using bone marrow chimeras Sekiguchi et al demonstrated 
that CD11b+ cells from the bone marrow infiltrate and accumulate in endometriosis lesions in 
a mouse model (125). These cells could represent a monocyte/ macrophage population, 
although CD11b+ cells could also constitute neutrophils, eosinophils and or certain subsets of 
dendritic cells (126). Capobianco et al demonstrated that bone marrow derived Tie2+ cells 470 
infiltrated endometriosis lesions in a mouse model, again demonstrating that bone marrow 
derived cells that ultimately express macrophage markers within lesions could be recruited 
from blood vessels (127).  
 
 475 
Figure 3. Endometriosis lesions are infiltrated by blood vessels, nerves and macrophages. 
Lesion resident macrophages are derived from macrophages originating from the 
endometrium and recruited macrophages. Macrophages interact with blood vessels and nerves 
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to stimulate their growth. Signalling also occurs between macrophages and stromal cells, 
which increases their clonal expansion and invasive properties. Created using Biorender.com. 480 
 
 
3.5.2. Macrophage phenotype and function in endometriosis.  Endometrial macrophages 
exhibit differential properties in endometriosis. Reflecting on the theory of retrograde 
menstruation and studies in mice identifying endometrial macrophages in lesions, the presence 485 
of macrophages in refluxed endometrial tissue in women has the potential to augment disease 
development in the peritoneal cavity. A number of studies have demonstrated perturbations in 
macrophage populations in the eutopic endometrium of endometriosis patients. Women with 
endometriosis have more endometrial macrophages that express lower levels of the 'wound-
healing' marker CD163 compared to women without disease, however the exact mechanisms 490 
behind these alterations are unknown (128, 129). Analogous to this, increased levels of CCL2 
can be observed in the endometrium of women with disease which corresponds to disease 
severity, suggesting increased influx of monocytes in disease that can then differentiate into 
macrophages (130). Increased matrix metalloproteinase-9 (MMP-9) co-localised with CD68+ 
macrophages in the endometrium of women with endometriosis is indicative of an increase in 495 
the number of macrophages implicated in tissue remodelling. This may enhance the ability of 
ectopic endometrial tissue deposits to implant in the peritoneal cavity (131). Whilst evidence 
of macrophage perturbations in the eutopic endometrium of women with endometriosis exists, 
the role of endometrial macrophages in endometriosis has not been defined as functional 
studies in this area are lacking.  500 
 
Women with endometriosis evidently have an increased number of peritoneal macrophages 
that exhibit a dysfunctional phenotype. Peritoneal macrophages collected from women with 
endometriosis have reduced phagocytic capacity due to low levels and activity of matrix 
metalloproteinase 9, which is required for extracellular matrix degradation and is regulated by 505 
prostaglandin E2 (PGE2)(38). In a co-culture system, in the presence of endometrial stromal 
cells isolated from ectopic endometrial tissues, monocyte-derived macrophages secreted IL-10 
and TGF-β, which in turn suppressed cytotoxicity and viability of NK cells(132), suggesting 
that macrophages are immunosuppressive in the presence of ectopic endometrial stromal cells 
and can act to suppress NK cells in the peritoneal cavity. Whilst a few studies have investigated 510 
peritoneal macrophages in women with endometriosis the cells have been evaluated as a global 
population and there are no studies pertaining to the constitution and function of the individual 
CRIghi and CRIglo populations of these cells: the abundance and behaviour of CRIghi population 
in women with endometriosis is not known, although inflammation and survival of refluxed 
endometrial tissue suggests that in endometriosis this tissue resident population could act to 515 
create a permissive and mitogenic environment for the formation of lesions. Analogous to this, 
a study by Beste et al demonstrated enhanced expression of both pro- and anti-inflammatory 
cytokines by macrophages collected from the peritoneal fluid of women with endometriosis, 
this could reflect the mixed population of cells present(133). The increased number of 
peritoneal macrophages in women with endometriosis suggests that in the condition the 520 
‘macrophage disappearance reaction’ (MDR) does not occur. Indeed, it has been previously 
demonstrated that in type-2 inflammation characterized by high level of IL-4 the MDR does 
not happen and peritoneal macrophages accumulate as a result of in situ proliferation(116). IL-
4 concentrations are elevated in the peritoneal fluid of women with endometriosis(134) 
suggesting that this could be a mechanism for macrophage accumulation. However, because 525 
the abundance of the different populations has not been characterized this hypothesis remains 
to be proven. Mouse models of endometriosis provide conflicting evidence of peritoneal 
macrophage dynamics: Yuan et al demonstrated that in a model that injects syngeneic, estradiol 
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primed, endometrial fragments into intact mice, those with endometriosis exhibited 
significantly lower numbers of LpM and more abundant SpM compared to control mice, 530 
consistent with the MDR. These perturbations in peritoneal macrophage populations were 
evident from 0.25 to 42 days post tissue injection(135). However, in a model injecting ‘menses-
like’ endometrial tissue into ovariectomised recipients supplemented with estradiol valerate, 
loss of LpM was not observed, and mice with endometriosis had more abundant LpM compared 
to naïve and sham animals (although the increase was not statistically significant(54). The 535 
second study seems to more closely recapitulate macrophage dynamics in women with 
endometriosis, although evidence is very limited. The differences observed in these two studies 
could be a result of several differences in experimental design including the nature of the donor 
endometrium injected into the peritoneal cavity as well as manipulations performed on the 
recipient mice. Yuan et al also demonstrated that in mice with endometriosis LpM exhibited a 540 
‘pro-inflammatory’ activation state and SpM were more ‘pro-repair’ in nature(135). This 
interpretation was based on expression of NOS2 (inflammatory) and CD206 (repair) and is 
contradictory to others studies reporting the pro-inflammatory status of SpM and pro-repair 
status of LpM in response to different inflammatory stimuli.  
 545 
Although it has been demonstrated that monocytes are recruited to lesions from the bone 
marrow, little evidence exists to characterise their role and dynamics once they infiltrate 
ectopic tissue. Johan et al examined infiltrating macrophage phenotype over time in 
endometriosis lesions in a heterologous mouse model and found that macrophage phenotype 
was progressively altered over time. Macrophages initially expressed pro-inflammatory 550 
markers iNOS and major histocompatibility complex II (MHC II), however at 7 and 14 days 
post lesion induction a higher proportion of macrophages expressed arginase 1 and CD204 
(scavenger receptor A), which are more associated with a tissue remodelling phenotype(136). 
This study therefore demonstrates that macrophage phenotype in endometriosis lesions is 
dynamic and progressively changes as lesions develop in the peritoneal cavity. However, as 555 
with other studies, the limited number of markers assessed makes it difficult to truly re-
capitulate the complex phenotype of macrophages in the tissue.  
 
Endometriosis lesions from women are highly infiltrated by CD68+ macrophages that are 
present within the stroma of the tissue and can also be found in close proximity to glands (42, 560 
53). Studies in women have strongly implied a role for macrophages in endometriosis, but the 
mechanistic studies performed in experimental models have significantly improved our 
understanding of the role of macrophages in the condition. Studies to date have largely focussed 
on defining the role of macrophages in syngeneic mouse models using various cell depletion 
approaches. A commonly utilised depletion method uses liposomes encapsulating 565 
bisphosphonates. These liposomes are taken up by phagocytic cells, which degrade the 
liposomes, releasing bisphosphonate and causing subsequent cell death. This method therefore 
selectively depletes phagocytic cells and is non-toxic to non-phagocytic cells, and has been 
commonly used to deplete phagocytic macrophage populations(137) . In a syngeneic mouse 
model of disease, Bacci et al used clodronate liposomes and a monoclonal anti-F4/80 antibody 570 
to deplete/inhibit peritoneal macrophage function in mice with induced endometriosis and 
demonstrated that both treatments caused a reduction in growth and blood vessel formation in 
lesions(53). Adoptive transfer of in vitro generated 'pro-inflammatory' (stimulated with IFN-
γ), 'anti-inflammatory' (stimulated with macrophage-colony-stimulating factor and IL-10) or 
'non-polarized' (stimulated with macrophage-colony-stimulating factor) macrophages lead to 575 
differential effects on lesion development. 'Non-polarized' macrophages had no effect on lesion 
number or weight, however adoptive transfer of pro-inflammatory macrophages reduced lesion 
weight. Conversely, adoptive transfer of anti-inflammatory macrophages caused an increase in 
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lesion weight. The authors noted that lesion architecture was also disrupted in mice which had 
received adoptive transfer of pro-inflammatory macrophages(53). Together, this data suggests 580 
that anti-inflammatory/ pro-repair macrophages may be important for the growth and 
development of lesions and pro-inflammatory macrophages have an antagonistic effect, 
clearing ectopic endometrial tissue and disrupting lesion architecture. Whilst this data provides 
an important insight into the roles of macrophage phenotypes in endometriosis, the use of the 
M1/M2 paradigm is limited and the exact phenotype and phenotypic heterogeneity of 585 
macrophages in endometriosis and their role in disease is currently unknown. Capobianco et al 
identified Tie-2 expressing macrophages that infiltrated mouse and human lesions. Depletion 
of Tie-2+ macrophages was achieved using a bone marrow chimera from mice expressing a 
suicide gene (herpes simplex virus type 1 thymidine kinase) expressed under control of the 
Tie2 promoter into wild-type mice. After treatment with ganciclovir (an anti-viral drug), bone-590 
marrow derived Tie2+ cells were selectively depleted and growth of endometriosis lesions was 
inhibited, with loss of neovascularisation and glandular organisation in the resultant 
lesions(127). Sekiguchi et al demonstrated that VEGFR1 knockout mice had smaller and less 
vascularised lesions than WT in a mouse model where sections of uterus were sutured onto the 
peritoneal wall. Using bone marrow chimeras they demonstrated that VEGFR1+ cells in lesions 595 
were bone marrow derived CD11b+ macrophages(125). WT endometriosis mice were also 
treated with clophosome N which depleted phagocytic cells in the peritoneal cavity at the time 
of endometriosis induction, and demonstrated that growth and angiogenesis in lesions was 
reduced(125). A similar study using liposomal bisphosphonate to deplete phagocytic peritoneal 
populations also demonstrated reduced growth of endometriosis lesions in a rat model(138). 600 
Thus, it seems clear that in experimental models of endometriosis, depletion of peritoneal 
phagocytic macrophage populations inhibits growth and angiogenesis of induced lesions.  
 
Endometriosis lesions exhibit cyclical bleeding in response to ovarian steroids in the same 
context as the eutopic endometrium, thus lesions can perceived as wounds undergoing recurrent 605 
tissue injury and repair(40). The process in lesions has been described to involve epithelial-
mesenchymal transition, fibroblast-myofibroblast transdifferentiation, smooth muscle cell 
metaplasia and fibrosis(139). Macrophages are critical for successful repair and regeneration 
in tissues; they stimulate local fibroblasts to differentiate into myofibroblasts to facilitate 
wound contraction(140). During wound repair the proliferation and expansion of local stromal 610 
cells is also regulated by macrophages and if the injury is severe, macrophages may activate 
additional stem cell and local progenitor cell populations that participate in repair (49). In line 
with these established roles in tissue injury and repair in vitro studies have aimed at assessing 
the interaction between endometrial stromal cells and macrophages in endometriosis. In a co-
culture system, culture of endometrial stromal cells with autologous macrophages isolated from 615 
women with endometriosis increased the invasive and clonogenic ability of stromal cells(141). 
Co-culture with ectopic endometrial stromal cells was also shown to decrease the phagocytic 
capacity of macrophages and increased the survival and proliferation of stromal cells compared 
to eutopic endometrial stromal cells in a study by Mei et al(142). A similar effect was also 
reported by Shao et al (143). Reciprocal signalling therefore appears to be occurring between 620 
ectopic endometrial stromal cells and macrophages, which could contribute to their survival 
and the formation of endometriosis lesions in the peritoneal cavity, however the precise 
mechanisms are yet to be elucidated and the specific macrophage populations involved are 
unknown. Stromal cells derived from ovarian endometrioma were found to express markers of 
mesenchymal stromal cells (MSCs), formed colony forming units and exhibited multipotency 625 
suggesting characteristics of mesenchymal stem-like cells. The MSCs from endometriomas 
promoted differentiation of monocytes to spindle shaped pro-repair / immunosuppressive 
macrophages in vitro(50). The results suggest that MSC influence macrophages such that they 
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exhibit an immunosuppressive phenotype and support lesion growth. The coordination of 
monocytes and macrophage activation states during inflammation and repair is tightly and 630 
temporally controlled. If disturbances occur at any point in the process this can lead to aberrant 
repair and the formation of pathological fibrosis(49). For example, persistent activation and 
sustained recruitment of pro-repair macrophages may contribute to pathological fibrosis(144). 
Since endometriosis lesions are undergoing consistent and repeated episodes of injury and 
repair and lesions exhibit fibrotic content, the events required for efficient, scarless repair may 635 
be disturbed. Depletion studies have demonstrated that macrophage depletion significantly 
reduces the fibrosis in lesions. Moreover, adoptive transfer of macrophages polarized in vitro 
to exhibit an M2a phenotype (activated with IL-4)) increased the fibrotic content of lesions 
(139). Thus, it seems that unlike the physiological wound repair process, endometriosis lesions 
cannot enter the resolution phase of inflammation and repair and the local inflammatory 640 
environment causes persistent activation of pro-repair macrophages that contribute to fibrosis.  
 
A role for macrophages in neurogenesis in endometriosis lesions has been established in the 
literature, suggesting a role in the generation of endometriosis-associated pain. Indeed, nerve 
infiltration in lesions is positively correlated with higher reported pain scores in women (145). 645 
Cholinergic, adrenergic, sensory Aδ and C nerve fibres have been identified in lesions(146, 
147), and macrophages are densely populated in areas of high nerve density(148, 149). Greaves 
et al reported that in response to estradiol, nerve fibres secreted CCL2 and CSF-1, which 
attracted macrophages, which in turn secreted neurotrophin 3 and brain-derived neurotrophin 
factor, stimulating neurogenesis (149).  Recently a role for macrophage-derived insulin-like 650 
growth factor-1 (IGF-1) as a key signal for nerve outgrowth and sensitization in endometriosis 
has also been described(150): depletion of peritoneal macrophages by clodronate liposomes 
reversed abnormal pain behaviour in mice with induced endometriosis and notably reduced the 
number of lesions in the peritoneal cavity, providing a direct link between macrophages and 
endometriosis-associated pain/lesion development. Macrophages treated with peritoneal fluid 655 
from women with endometriosis exhibit an up regulation of IGF-1 at the mRNA level, and 
mechanistically macrophage-derived IGF-1 increased the growth of embryonic rat dorsal root 
ganglion explants and this was reversed by an IGF-1 inhibitor. Similarly, IGF-1 inhibition by 
the IGF-1 receptor inhibitor linsitinib in a mouse model could reverse abnormal pain 
behaviours(150). Taken together, macrophages are evidently pivotal to facilitating 660 
neurogenesis and the generation endometriosis-associated pain symptoms, and this is at least 
in part mediated by IGF-1. The reciprocal signalling that occurs between macrophages and 
nerve fibres therefore appears critical in regulating neurogenesis in lesions and 
neuroinflammation is a key driver of endometriosis pathophysiology. 
 665 
Studies mechanistically indicate that macrophages play key roles in growth, vascularization 
and neurogenesis in lesion, as well as generating pain in the condition and these experiments 
have given insight into some of the factors expressed by macrophages the phenotype of 
macrophages in endometriosis has not been fully characterized. Macrophages in endometriosis 
lesions have long been described as being wound healing and 'M2-like', however few studies 670 
have taken into consideration the complexities of macrophage phenotype, where pro-
inflammatory and wound-healing like markers often co-exist in response to complex signals 
from the local tissue microenvironment(76). In humans, lesion resident macrophages express 
the scavenger receptors CD163 and CD206, associated with haemoglobin scavenging and 
silent clearance of debris(53). Cominelli et al also identified CD163+ CD206+ macrophages in 675 
superficial lesions from women, which also expressed high levels of matrix metalloproteinase-
27, associated with tissue remodelling(151). Duan et al characterised nitric oxide synthase 
(iNOS+) pro-inflammatory and CD163+ wound healing-like macrophages in mouse 
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endometriosis lesions(139). In a rhesus macaque model of endometriosis, lesions were highly 
infiltrated by CD163+ macrophages(152). Whilst macrophages in endometriosis lesions 680 
possessing a 'wound healing' like phenotype is synergistic with their role in growth and 
angiogenesis in lesions, a more comprehensive analysis of macrophage phenotype in 
endometriosis lesions is required.  It is also unknown whether different phenotypes exist within 
endometriosis lesions, which could play differential roles in pathology, and identifying these 
populations is key for understanding which macrophage populations are driving pathology.  685 
 
Identification of endometrial macrophages and bone-marrow monocyte-derived macrophages 
in endometriosis lesions demonstrates that endometriosis-associated macrophages have 
different origins, however differential roles for these populations have not yet been 
investigated. It is possible that the endometrial macrophages in lesions are monocyte-derived 690 
since a rapid influx of classical monocytes into the endometrium is observed during 
endometrial repair. Evidence of embryonically derived tissue resident macrophages in lesions 
is yet to be demonstrated. Previous studies have demonstrated that depletion of peritoneal 
macrophages has pronounced effects on lesion size and vascularization(53), depletion of this 
population translates to reduced number of macrophages in lesions and attenuates pain in 695 
mice(54). It remains unknown how endometrial and recruited monocytes contribute to lesion 
establishment and maintenance.  Depletion of different macrophage populations prior to 
inducing endometriosis in mice and at different time-points during the life-course of the lesion 
will yield important insights into the role of these pivotal cells in the disorder. Whilst 
macrophages from 3 origins have been described the true heterogeneity of macrophage 700 
phenotype in lesions and in the peritoneal fluid, in endometriosis, is unknown. Application of 
single cell discovery techniques and digital molecular pathology could provide vital 
information on the complexities of endometriosis-associated macrophage phenotype, and 
coupled with in vivo functional studies identification of a disease-promoting population that 
exhibits unique markers that differ from healthy macrophages may be possible.  705 
4. The future: macrophage targeted therapies 
Macrophages offer an attractive therapeutic target due to their instrumental role in a number of 
pathologies(79). Inhibition of macrophage signalling or recruitment, as well as re-education of 
disease-associated macrophages to a 'healthy' phenotype could be of clinical benefit to patients 
where macrophages are implicated in disease pathophysiology. Identification of disease 710 
promoting macrophage populations and a detailed understanding of their regulation, 
recruitment and phenotype is a fundamental step before the development of therapeutics which 
specifically target disease-associated macrophages is possible. Due to the pivotal role that 
macrophages play in many cancers, macrophage-targeted therapies have received much 
attention in the literature and a number of in vivo studies and clinical trials have demonstrated 715 
efficacy in using macrophage-mediated treatments to improve clinical outcomes(79). A subset 
of studies has targeted proliferation of TAMs in an effort to alleviate tumour burden and 
improve clinical outcomes. Strachen et al demonstrated that targeting the Csf-1-receptor with 
a small molecule inhibitor attenuated the turnover rate of TAMs and decreased tumour growth 
in mouse models of breast and cervical cancer(153). A phase I trial demonstrated a significant 720 
reduction in macrophage number in solid tumours after anti-Csf-1r treatment(154), and Csf-1r 
inhibition showed an improvement in clinical outcomes including improvement of symptoms 
in patients with diffuse-type giant cell tumours(155). Inhibiting macrophage proliferation 
therefore appears to be of clinical benefit in cancer models and subsets of cancer patients. 
Future treatments should aim to specifically target disease-associated macrophage populations; 725 
Csf-1 is a key regulator of macrophage proliferation and survival in most tissues and 
neutralization or inhibition would affect healthy macrophage populations and as such is not an 
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ideal therapy. (156). The proliferative capacity of endometriosis lesion-resident macrophages 
is currently unknown, thus further research is required to determine whether this treatment 
strategy would be of benefit to women with endometriosis.  730 
 
Another potential mechanism of therapeutic intervention could involve blocking recruitment 
of disease-promoting macrophage populations. The CCL2/ CCR2 recruitment mechanism is 
implicated in a number of cancers and a CCR2 inhibitor to be administered alongside 
chemotherapy is currently in phase 1b trials (157). Inhibition of recruitment may be beneficial 735 
in blocking infiltration of macrophages into endometriosis lesions, however the mechanisms, 
which regulate recruitment into lesions, are currently poorly understood. 
Whilst progression of research into macrophage-targeted therapies is promising, current 
therapies do not specifically target disease-promoting macrophages but have the potential to 
affect macrophage populations throughout the whole body. However, as our understanding of 740 
disease-modified macrophages improves, it is evident that establishing macrophage origins and 
phenotype heterogeneity in disease are crucial areas of research before specific, targeted 
treatments can be designed (72). Future work describing macrophage sub-populations, active 
recruitment mechanisms and macrophage phenotype in endometriosis is therefore critically 
required before macrophage-targeted treatments may be a possibility for women with 745 
endometriosis.  
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